The dual effect of VEGF limits the use of either pro- or anti-VEGF strategies (e.g., anti-VEGF monoclonal antibodies/small molecule VEGFR inhibitors and mesenchymal stem cells engineered to produce VEGFA, respectively) in the treatment of CNS disorders (reviewed by Shim and Madsen, 2018). This evidence concerns the gene KDR and central nervous system disorder.